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The response of peripheral B cells to T-
  dependent antigen involves a highly orches-
trated series of changes. These are manifested 
by successive alterations in responsiveness to 
external signals, anatomic relocalization with 
pas  sage through the germinal center (GC), mod-
ifi  cations in Ig genes by somatic hypermutation 
(SHM) and class switch recombination (CSR), 
and the assumption of alternative fates as long-
lived memory cells or Ig-secreting plasma cells 
(1). This multistep process of diff  erentiation is 
governed by an interlocking chain of transcrip-
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tion factors, some of which function as “master 
regulators” of developmental decision points, 
each with its own set of target genes (2–4).
Among these factors, activation of NF-κB 
downstream of CD40 is required for initia-
tion of the GC reaction (5) and induction of 
  activation-induced cytidine deaminase (AICDA) 
(6), a protein required for SHM and CSR. 
BCL6 is also required for the formation of GC, 
where it acts in a B cell–autonomous manner 
to repress genes involved in the control of 
lymphocyte activation and cell cycle progres-
sion, allowing rapid cell proliferation (4). BCL6 
also arrests further development by acting in 
concert with PAX5 (BSAP) to repress genes 
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Interferon (IFN) consensus sequence-binding protein/IFN regulatory factor 8 (IRF8) is a 
transcription factor that regulates the differentiation and function of macrophages, granu-
locytes, and dendritic cells through activation or repression of target genes. Although IRF8 
is also expressed in lymphocytes, its roles in B cell and T cell maturation or function are ill 
defi  ned, and few transcriptional targets are known. Gene expression profi  ling of human 
tonsillar B cells and mouse B cell lymphomas showed that IRF8 transcripts were expressed 
at highest levels in centroblasts, either from secondary lymphoid tissue or transformed 
cells. In addition, staining for IRF8 was most intense in tonsillar germinal center (GC) dark-
zone centroblasts. To discover B cell genes regulated by IRF8, we transfected purifi  ed 
primary tonsillar B cells with enhanced green fl  uorescent protein–tagged IRF8, generated 
small interfering RNA knockdowns of IRF8 expression in a mouse B cell lymphoma cell line, 
and examined the effects of a null mutation of IRF8 on B cells. Each approach identifi  ed 
activation-induced cytidine deaminase (AICDA) and BCL6 as targets of transcriptional 
activation. Chromatin immunoprecipitation studies demonstrated in vivo occupancy of 5′ 
sequences of both genes by IRF8 protein. These results suggest previously unappreciated 
roles for IRF8 in the transcriptional regulation of B cell GC reactions that include direct 
regulation of AICDA and BCL6.
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involved in plasmacytic diff  erentiation (2). These genes in-
clude PRDM1 (BLIMP1) (2), a direct target of BCL6, and 
XBP1 (7), a target of PAX5. Commitment to plasmacytic 
diff  erentiation appears to initiate within the GC, marked by 
the appearance of cells with an incomplete plasma cell phe-
notype. These cells are PNA+ in the mouse but do not ex-
press BCL6 or PAX5; instead, they are positive for CD138 
(Syndecan), BLIMP1, and a member of the IFN regulatory 
factor (IRF) family, IRF4. The importance of carefully reg-
ulated expression of these genes to normal B cell diff  eren-
tiation is indicated by the fact that aberrant expression of 
NF-κB, BCL6, BLIMP1, PAX5, and IRF4 as a result of chro   -
mosomal translocations is associated with a variety of human 
non-  Hodgkin’s lymphomas (8).
In this paper we report that another member of the 
IRF family of transcription factors, IRF8 (also known as 
IFN consensus sequence-binding protein [ICSBP]) (9), is 
diff   erentially expressed during normal B cell activation, 
with peak levels in GC dark-zone centroblasts and lowest 
levels in Ig-secreting populations of plasma cells and plas-
mablasts. IRF8 is a hematopoietic cell–specifi  c member of 
the IRF family of transcription factors (9–11). It is ex-
pressed constitutively in macrophages, B cells, and some 
DCs and at low levels in resting T cells and granulocytes. 
Studies of mice with a null mutation of the gene (IRF8−/−) 
(12) showed that IRF8 controls myeloid diff  erentiation 
by promoting macrophage development while inhibiting 
granulocyte diff  erentiation (12–14). IRF8 also regulates the 
maturation and function of subsets of DCs and Langerhans 
cells, thus providing a critical link between innate and ac-
quired immunity (15–17).
IRF8 functions as a transcriptional activator or repressor 
through the formation of diff   erent DNA-binding hetero-
complexes with a series of proteins including IRF family 
members (IRF1 and -2) (18) and Ets family members (PU.1 
and TEL) (19, 20), as well as E47 (19), NFATc1 (21), Trip-
15/CSN2 (22), and Miz-1 (23). As part of these complexes, 
IRF8 can exhibit direct binding to target DNA sequences, 
including the IFN-stimulated response element and the Ets/
IRF composite element (EICE) (10, 11), as well as a newly 
recognized consensus sequence comprising an IRF/Ets com-
posite element distinct from EICE (24); however, IRF8 is 
also recruited to IFN-γ activation and isolated Ets sites in a 
nonbinding capacity through protein interactions (10, 25). It 
is noteworthy that these associations do not necessarily take 
place in all mammalian cells, as a functional association of 
IRF8 with Miz-1 occurred in hematopoietic but not NIH3T3 
cells (23), whereas interactions of IRF8 and IRF4 capable of 
repressing expression of the gene ISG-15 (G1P1) were func-
tional in macrophages but not B cells (26).
Targets of transcriptional regulation by IRF8 and its part-
ners have been studied in macrophages, granulocytic cells, 
and DCs. They include a series of genes involved in innate 
and adaptive immunity including IL-12p40, IL-18, toll-like 
receptor 4, Dab2, gp91-phox, and IL-1β, as well as those 
regulating apoptosis (BCL-XL and BCL2) (10, 11, 24–27). In 
addition, a series of studies has implicated IRF8 in the devel-
opment of human chronic myelogenous leukemia (27–31), 
where it functions as a tumor suppressor gene that modulates 
the transforming activity of the BCR/ABL protooncogene 
in vivo (30) and in vitro (31).
In contrast to this rapidly expanding understanding of the 
contributions of IRF8 to myeloid development, function, 
and transformation, very little is known about the role played 
by this gene in lymphoid cells. Roles in B cell diff  erentiation 
and function were suggested by the fi  ndings that IRF8−/− 
mice (12) have increased numbers of splenic and LN B cells. 
Mice defi  cient in both IRF8 and IRF4, a second hematop-
oietic cell–specifi  c IRF family member (32, 33), exhibited a 
block in B cell development at the pre-B to B transition, a 
defect not seen in mice singly defi  cient in these factors (34). 
This phenotype was associated with a striking reduction in 
the rearrangement of Ig L chain genes. A likely role for IRF8 
in regulating Ig L chain expression is also indicated by the 
fi  ndings that PU.1, E47, and Spi-B recruit IRF8 and IRF4 to 
EICE in the Igκ 3′ and λ enhancers (35–37). The possibility 
that regulated expression of IRF8 might be involved in later 
events in B cell diff  erentiation was further suggested by the 
fi  nding that the gene most stringently down-regulated during 
the maturation of human B cells from CD19+ tonsillar B cells 
to plasma cells was IRF8 (38).
The current studies of IRF8 expression and transcrip-
tional regulation in B cell lineage cells were prompted by 
parallel analyses of expression profi  les exhibited by diff  erent 
classes of mouse B cell lineage lymphomas (39, 40) and sub-
sets of human primary tonsillar B cells (41, 42). These studies 
showed that the gene that best distinguished mouse centro-
blastic (CB) diff  use large B cell lymphomas from other lym-
phoma classes was IRF8 and that IRF8 was expressed at 
higher levels in tonsillar GC centroblasts than in less or more 
mature primary human B cells. In addition, we found that 
IRF8 regulates the expression of genes critically involved in 
GC including AICDA and BCL6, which were shown to be 
direct transcriptional targets by promoter reporter and chro-
matin immunoprecipitation (ChIP) analyses.
RESULTS
High-level expression of IRF8 is a distinguishing feature of 
mouse CB lymphomas
We used a 70mer oligonucleotide array interrogating 6,800 
genes to establish expression profi  les for 10 classes of mouse 
B cell lineage lymphomas (43, 44). A t test was used to iden-
tify genes that distinguished each subset from all the others. 
IRF8 was the gene that best distinguished the histologically 
defi  ned CB subset of diff  use large B cell lymphomas (unpub-
lished data). Analyses of the relative expression of IRF8 tran-
scripts among the lymphoma classes showed that the highest 
levels were seen in CB and the other GC-derived lympho-
mas,    with transcript levels in CB being around sixfold 
higher than in the lowest-expressing class, plasmacytomas 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20051450/DC1). These results paralleled earlier studies JEM VOL. 203, January 23, 2006  65
ARTICLE
of normal human primary B cells that showed that the levels 
of IRF8 transcripts were  10-fold higher in total tonsillar 
CD19+ B cells than in BM plasma cells (38). This suggested 
that the pattern of IRF8 expression seen with mouse lym-
phoma subsets was likely to refl  ect diff  erences related to the 
diff  erentiative state of the cell of origin rather than a mecha-
nistic contribution to transformation.
IRF8 expression is modulated during the human GC reaction
To evaluate a possible relationship between levels of IRF8 
expression and stages in normal B cell diff  erentiation, we 
turned to studies of human primary tonsillar B cells. Previ-
ous studies demonstrated that eight subsets of CD19+ B cells 
can be distinguished by fl  ow cytometry using antibodies to 
IgD and CD38 (Fig. 1 A) (41, 42): IgD+ preswitch pop-
ulations (CD38−IgD+, CD38+IgD+, and CD382+IgD+), 
CD382+IgD− (GC dark-zone centroblasts), CD38+IgD− (GC 
light-zone centrocytes), CD38−IgD−, CD38+++IgD+ (plas-
mablasts), and CD38+++IgD− (plasma cells). [ID]FIG1[/ID]
Gene arrays were used to quantitate transcripts in primary 
human tonsillar and peripheral blood B cell (PBB) subsets 
(Fig. 1 B). We monitored levels of transcripts for genes known 
to change in expression in association with GC passage and 
subsequent maturation to memory and plasma cells: BCL6, 
IRF4, AICDA, CD38, XBP1, and PRDM1 (BLIMP1) (Fig. 
1 B). Transcripts for BCL6 and AICDA were highest in CB 
and decreased in memory and plasma cells. In ad  dition, tran-
scripts for CD38, IRF4, PRDM1, and XBP1 were highest in 
plasma cells. These results are completely in keeping with ear-
lier studies of tonsillar B cell subsets using microarrays or serial 
analysis of gene expression (45, 46), validating the methods 
used to subset the tonsillar B cell populations. Notably, tran-
scripts for IRF8 were highest in CD38++IgD− centroblasts.
RNA prepared from the sorted tonsillar subsets and puri-
fi  ed IgD+ and IgD− PBB was then examined by quantitative 
RT-PCR (qPCR) for expression of IRF8 transcripts, with 
results normalized against levels in sorted IgD+ PBB (Fig. 
1 C). Of note, transcripts were higher in nonsecreting B cells 
in activated secondary lymphoid tissue than in circulating 
B cells. The results also showed that IRF8 transcripts were 
highest in centroblasts (6-fold over PBB), lower in pre- and 
postswitch populations (2–4-fold), and lowest in Ig-secreting 
cells ( 0.5-fold).
We next evaluated expression of some of these genes at 
the protein level using immunohistochemistry to study fro-
zen sections of human tonsil. As expected, IRF8 was ex-
pressed in cells of the myeloid lineage with high levels in 
extrafollicular elements including macrophages, monocytes, 
granulocytes, and DCs (Fig. 2 A). [ID]FIG2[/ID] Cells of the follicular man-
tle zone were mostly negative except for a minor population 
of small lymphoid cells. In contrast, all GC were positive, 
with large centroblast-like cells staining most intensely. We 
used two-color studies to examine expression of CD23, a 
marker of follicular mantle cells, BCL6, which is expressed 
most highly in centroblasts, and IRF8 (Fig. 2, B and C). 
Within GC, antibodies to IRF8 showed intense nuclear 
staining of cells in the dark zone. This reactivity colocalized 
with nuclear staining for BCL6. In addition, IRF8+ cells 
were almost all positive for Ki-67, a marker for the highly 
proliferative population of centroblasts (not depicted).
Figure 1.  Expression of IRF8 transcripts in human tonsillar and 
PBBs. (A) Subsets of tonsillar B cells as defi  ned by expression of IgD and 
CD38 were purifi  ed by fl  ow cytometric sorting. RNA prepared from sorted 
cells belonging to each fraction was used to quantitate IRF8 expression. 
(B) Quantitation of transcripts of the indicated genes as determined 
by array analyses of purifi  ed tonsillar and peripheral B cell subsets. 
Data for each gene were normalized to levels in IgD+ PBBs. (C) qPCR 
 analyses  of  IRF8 transcripts in sorted PBB (IgD+ and IgD−) and in purifi  ed 
subsets of tonsillar B cells. Results were normalized to transcript levels 
in IgD+ PBB. PB, plasmablasts; PC, plasma cells. Data are expressed as 
means ± 1 SEM compared with IgD+ PBB for two (B) or three to four 
(C) independent experiments.66   REGULATION OF THE GC GENE PROGRAM BY IRF8/ICSBP | Lee et al.
IRF8 regulates the expression of genes involved 
in the GC reaction
We applied three approaches to identifying genes regulated 
by IRF8 in B cell lineage cells. First, we transfected primary 
CD19+ tonsillar B cells with a construct expressing an en-
hanced GFP (EGFP)–tagged WT mouse IRF8. Because 
IRF8 positively regulates its own expression (10), this al-
lowed us to monitor human IRF8 expression from the en-
dogenous locus using species-specifi  c primers. We also used 
a second construct that expressed only EGFP. The cells ex-
pressing either EGFP alone or EGFP-tagged IRF8 were 
sorted into EGFP+ and EGFP– fractions (Fig. S2, http://
www.jem.org/cgi/content/full/jem.20051450/DC1, and the 
transcript levels for various genes were assessed by qPCR. Of 
note, FACS analyses of EGFP levels at 18 h after transfection 
showed that IRF8 was equally well expressed in the eight 
subsets of tonsillar B cells (unpublished data).
These studies showed that human IRF8 transcripts in the 
EGFP+ population expressing mouse IRF8 were increased 
an average of 6.5-fold over the levels in cells expressing EGFP 
alone (Fig. 3), confi  rming the predicted autoregulation of the 
gene and validating the experimental system. [ID]FIG3[/ID] Expression of 
two known IRF8 targets, VPREB (34) and NF1 (not de-
picted) (47), was increased 5.6- and 2.4-fold, respectively. 
Further analyses showed that cells with enhanced expression 
of IRF8 had increased levels of transcripts for mature B cell/
GC-related genes AICDA and BCL6. These experiments 
suggested that AICDA and BCL6 are transcriptionally regu-
lated by IRF8, either as direct or indirect targets.
In a second approach to discovering genes regulated by 
IRF8, we used small interfering RNA (siRNA) to knock 
down IRF8 expression in the mouse follicular lymphoma–
  derived B cell line NFS-202. The cells were infected with a 
retrovirus that expressed puromycin and either of two siRNA 
for IRF8 or a nonreactive siRNA. After selection for puromy-
cin resistance, cloned cells were assayed for levels of IRF8 
transcripts by qPCR. We selected two independent clones, 
one expressing siRNA #2 and one expressing siRNA #5, in 
which Irf8 transcripts were reduced to levels 10% or less of 
those expressed by control cells when normalized to levels of 
β-actin or Gapdh (unpublished data). By immunoblotting, the 
siRNA construct reduced IRF8 protein to 10% or less of control 
levels with α-tubulin serving as a loading control (Fig. 4 A). [ID]FIG4[/ID]
RNA prepared from these clones was examined by 
qPCR. Transcripts for Aicda and Bcl6 were strikingly reduced 
(Fig. 4 B), reinforcing the suggestion that IRF8 functions as 
a transcriptional activator for both genes. To investigate the 
possibility that IRF8 directly regulates Aicda and Bcl6 gene 
expression, we cloned putative promoter fragments fl  anking 
the start sites of both genes and placed them upstream of a 
  luciferase reporter gene. Transient expression of the reporters 
in HeLa cells with increasing amounts of an IRF8 expression 
plasmid showed a greater than fi  vefold increase in activity of 
the Bcl6 reporter and a greater than threefold increase for the 
Aicda reporter (Fig. 4 C).
Figure 2.  Immunohistochemical staining of frozen sections from 
tonsil. (A) Staining for IRF8 at an original magnifi  cation of 10. (B and C) 
Staining on serial sections for IRF8 and CD23 (B) and BCL6 and CD23 
(C) at an original magnifi  cation of 20. Areas comprising the GC dark zone 
(DZ) and follicular mantle zone (FM) are indicated. Results are representa-
tive of three experiments.
Figure 3.  Transcript levels measured by qPCR for genes in total 
tonsillar B cells transfected with EGFP-tagged WT IRF8 or EGFP 
only and sorted 18 h later for EGFP+ and EGFP cells. Data are from 
independent studies (three for VPREB and nine for IRF8, AICDA, and 
BCL6). Numbers indicate the fold change represented by the closed bars. 
Values indicate SD.JEM VOL. 203, January 23, 2006  67
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As a third approach to understanding genes regulated by 
IRF8 in B cells, we examined mice homozygous for a null 
mutation of the gene (−/−) or WT animals (+/+) (12). 
Histologic studies of spleens and LN from young −/− mice 
showed the previously described accumulations of granulo-
cytes, macrophages, and pseudo-Gaucher cells in association 
with lymphadenopathy and splenomegaly. GC were readily 
identifi  ed in lymph nodes and spleens of both +/+ and 
−/− mice. Those of +/+ mice were compact and well de-
fi  ned, with centrocytes and centroblasts exhibiting charac-
teristic nuclear staining for BCL6 and surface staining for 
PNA (Fig. 5). [ID]FIG5[/ID] GC of −/− mice exhibited comparable stain-
ing of the B cell population but were usually less well or-
ganized. Some, as shown in Fig. 5, had populations of 
BCL6+PNA+ cells trailing away from a more dense collec-
tion of cells like those seen in +/+ GC. Others had substan-
tial numbers of small BCL6− lymphocytes localized in small 
clusters and dispersed throughout a loosened structure of 
BCL6+PNA+ cells along with scattered apoptotic bodies not 
seen in +/+ GC (unpublished data).
To determine how these histologic features related to ex-
pression of GC-associated genes, RNA prepared from puri-
fi  ed splenic B cells of +/+ and −/− mice was analyzed by 
qPCR for levels of transcripts of Aicda and Bcl6 normalized 
to transcript levels for Gapdh. The results (Fig. 6 A) showed 
that, compared with levels in +/+ B cells, Aicda and Bcl6 
transcripts were reduced approximately two- and threefold, 
respectively. [ID]FIG6[/ID] These fi  ndings support the conclusion that IRF8 
is involved in the transcriptional regulation of Bcl6 and Aicda 
Figure 4.  Effect of IRF8 on expression of BCL6 and AICDA. 
(A) Western blot analyses of IRF8 and α-tubulin expression in NFS-202 
cells expressing a negative siRNA and clones expressing either suppressive 
siRNA #2 or #5. (B) qPCR analyses of gene transcripts in comparisons of 
NFS-202 cells with an inactive siRNA (closed bar) or with active siRNA #2 
and #5 (open and shaded bars, respectively). Results obtained with cells 
with IRF8 siRNAs are normalized to the values for cells with the control 
siRNA. Results are representative of three experiments. (C) Luciferase 
reporter assays of Bcl6 and Aicda promoter sequences. HeLa cells were 
cotransfected with 800 ng pGL3-Bcl6 or pGL3-Aicda reporter vector, 
0–300 ng pCDNA3.1-IRF8 or pCDNA3.1 empty expression vector, and 
50 ng pRL-SV40 reporter vector. Luciferase activities were measured after 
22 h, and transfection effi  ciency was normalized with values of Renilla 
luciferase activities. Results are representative of three experiments. Val-
ues in B and C indicate SD.
Figure 5.  Immunohistochemical studies of LN from WT (+/+) and 
IRF8-defi  cient (−/−) mice. Frozen serial sections were stained with 
anti-BCL6 or PNA and counterstained with hematoxylin. Original magnifi  -
cations are indicated.68   REGULATION OF THE GC GENE PROGRAM BY IRF8/ICSBP | Lee et al.
and showed that reduced expression of these genes was asso-
ciated with poorly organized GC in mutant mice.
IRF8 is bound to the endogenous AICDA and BCL6 
promoters in mouse and human B cells
We performed ChIP analyses to determine whether IRF8 
protein was bound in vivo to promoters of genes that it ap-
peared to regulate. As likely positive targets, we selected re-
gions in the promoters of the mouse and human BCL6 and 
AICDA genes. Protein from the mouse NFS-202 cell line or 
human tonsillar B cells was cross-linked to DNA using form-
aldehyde, and immunoprecipitations were performed with 
anti-IRF8 or control antibodies. After cross-linking was 
  reversed, the DNA was amplifi  ed with species- and gene-
  specifi  c primers for the promoter regions of AICDA and 
BCL6. Primer pairs for AICDA and BCL6 amplifi  ed DNA 
products of the expected sizes from the total input DNA at 
specifi  c locations in the 5′ sequences but not at 10-kb sites 5′ 
of these targets (Fig. 6 B). Notably, bands were observed only 
with anti-IRF8–precipitated DNA. These data indicated that 
IRF8 bound the endogenous promoters of AICDA and 
BCL6 in a mouse GC B cell–derived cell line and in human 
tonsillar B cells.
DISCUSSION
The GC reaction is the hallmark feature of the B cell re-
sponse to T cell–dependent antigen. Studies using DNA mi-
croarray and SAGE analyses, primarily of human cells, have 
identifi  ed large numbers of genes that are diff  erentially ex-
pressed as cells move into and through the GC, maturing 
from the naive state to CB, to centrocytes, and then to mem-
ory or plasma cells as they exit (38, 45, 46, 48, 49). A substan-
tial number of these genes are transcription factors. Among 
them are a series of “master regulators”—PAX5, BCL6, 
PRDM1, and XBP1—situated at critical developmental de-
cision points and forming a transcriptional regulatory cascade 
in which they function in a hierarchic as well as a combinato-
rial fashion to govern the diff  erentiation of B cells involved 
in the GC reaction (2–4, 7). The transcriptional functions of 
these master regulators are complex, involving both gene ac-
tivation and repression as well as mutual antagonism.
The data from this study identify the transcription factor, 
IRF8, as another important regulator of the GC program of 
molecular diff  erentiation by demonstrating two striking and 
previously unappreciated roles in B cell biology, the direct 
transcriptional activation of both BCL6 and AICDA, critical 
determinants of GC development, and function and eff  ects 
on GC organization. By activating BCL6, a known repressor 
of PRDM1, IRF8 may also function to prevent GC B cells 
from initiating a plasma cell diff  erentiation program. Studies 
of mice homozygous for a null allele of IRF8 showing that 
transcripts for both Bcl6 and Aicda were reduced approxi-
mately two- to threefold in isolated B cells strongly support a 
direct role for IRF8 in regulating their expression.
Neither BCL6 nor AICDA was previously identifi  ed as 
a transcriptional target of IRF8. BCL6 is absolutely required 
for GC formation, and control of expression is known to be 
regulated at multiple levels (50–52). Although transcripts can 
be detected at low levels in several tissues, protein expression 
is limited to lymphocytes (53). Within the B cell lineage, 
BCL6 is expressed only in mature B cells of the GC. In B 
cells, protein levels are modulated by phosphorylation and 
ubiquitination, resulting in proteasomal degradation, whereas 
acetylation negatively regulates BCL6 function (51, 52). 
Transcriptional down-regulation of Bcl6 appears to be re-
quired for B cells to exit the GC, and our experiments indi-
cate that this may be caused by synchronous reductions in the 
expression of IRF8 and activation of BLIMP1, a transcrip-
tional repressor of Bcl6 (2).
AICDA is a critical determinant of GC formation and 
function. Defi  ciencies in AICDA in humans and mice result 
in markedly impaired CSR and SHM and, in contrast to 
mice defi  cient in BCL6, very large GC (54, 55). AICDA 
transcripts are detected only in peripheral lymphoid tissues, 
where they are almost exclusively associated with GC (56). 
AICDA can be induced in resting B cells by several exoge-
nous stimuli including IL-4, CD40, TGF-β, or LPS (56, 57), 
BLys or APRIL (58), or IL-21 (59) alone or in diff  erent com-
binations. Our data strongly suggest that IRF8 is downstream 
of the signaling cascades initiated by these agents in B cells 
and plays a role in regulating expression of AICDA in the 
GC. Earlier studies showed that the levels of switched Ig 
classes in activated cells from AICDA+/− and AICDA+/+ 
mice were comparable, indicating that a 50% reduction in 
AICDA expression had no major eff  ect on CSR (6). The fact 
that AICDA transcripts were  37% of normal in B cells from 
the KO may explain why levels of switched Ig classes were 
close to normal in IRF8−/− mice (60).
Immunohistochemical studies demonstrated that both 
IRF8 and BCL6 are expressed in GC B cells localized to the 
Figure 6.  Relations of IRF8 to expression of BCL6 and AICDA. 
(A) RNA prepared from splenic B cells from IRF8-defi  cient and WT mice 
was tested by qPCR for expression of Bcl6 and Aicda. Data for IRF8−/− 
B cells are normalized to levels in +/+ B cells and indicate the means ± 
SEM for four mice. (B) IRF8 is present at the promoter regions of BCL6 
and AICDA in vivo. ChIP analyses were performed with mouse NFS-202 
cells or purifi  ed human tonsillar B cells. Protein–DNA complexes were 
immunoprecipitated by addition of antibody to IRF8 and analyzed by PCR 
for the presence of BCL6 and AICDA promoter sequences. Data are repre-
sentative of three experiments.JEM VOL. 203, January 23, 2006  69
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dark zone. In contrast, expression of the other lymphoid-
  restricted member of the IRF family, IRF4, is limited to a 
small population of centrocytic B cells in the light zone, as 
well as a few plasmablasts and plasma cells (53). Expression of 
IRF4 in B cells is regulated primarily by pathways known to 
drive lymphocyte activation rather than by IFN, which is the 
case for most other IRF family members. Stimuli provided 
by IL-4, CD40, and Ig cross-linking received by cells during 
selection in the GC not only activate IRF4 but also repress 
BCL6, providing a likely explanation for the contrasting ex-
pression patterns of these two genes (61). Whether down-
regulation of IRF8 or altered expression of its binding partners 
plays a role in down-regulating the expression of BCL6 is 
currently not known but is worth considering. A mechanistic 
basis for the contrasting patterns of IRF8 and IRF4 expres-
sion has not been defi  ned, but the promoter regions of the 
two genes are apparently regulated by distinct members of 
the STAT family (STAT1 in the case of IRF8 and STAT6 
for IRF4) (62). The nature of the signals that induce the ex-
pression and activity of IRF8 in the tonsil is currently un-
known but of great interest.
The approaches used to defi  ne transcriptional targets of 
IRF8 all have limitations. First, the knockdown studies were 
based on the use of a mouse cell line derived from a lym-
phoma with associated uncertainties about changes in gene 
expression patterns that might have occurred during the pro-
cess of transformation or on adaptation to tissue culture. In 
addition, the use of stable siRNA knockdowns makes it diffi   -
cult to determine which eff  ects of IRF8 on gene expression 
are primary or secondary.
Second, splenic B cells from the IRF8 KO mice devel-
oped in an abnormal cellular environment caused by exten-
sive myeloid proliferation and a T helper type 2 cell–based 
cytokine milieu defi  cient in IL-12 and IFN-γ (12). Although 
IRF8 has not been shown to play a role in the development 
or function of follicular DCs, it has profound eff  ects on sub-
sets of DCs and Langerhans cells (15–17). Irregularities in the 
organization of follicles and GC in secondary lymphoid tissue 
of IRF8-null mice may well be caused by IRF8-dependent 
changes in the development and function of follicular DCs.
Third, the studies of total tonsillar B cells for eff  ects of 
IRF8 overexpression were performed 18 h after transfection. 
This again leaves open the issue of primary versus secondary 
targets of IRF8 regulation. Finally, there are several diff  er-
ences between the immunology of mice and humans (63, 
64), and conclusions drawn from cross-species comparisons 
must be made with caution. Nonetheless, the studies of 
IRF8-defi  cient mice, the ChIP experiments, and the tran-
scriptional reporter assays all argue that BCL6 and AICDA 
are primary targets of IRF8 in both species.
In conclusion, our experiments identify IRF8 as a novel 
component of the regulatory cascade that moves B cells into 
and through the GC reaction. Increased levels of IRF8 in 
GC B cells appear to play a role in fostering the GC response 
by up-regulating BCL6 and AICDA, and down-regulation 
of expression may contribute to GC B cell entry into the 
plasma cell diff  erentiation program. Because GC can form in 
IRF8-defi  cient mice, IRF8 appears to function as a rheostat 
that modulates B cell diff  erentiation and function during the 
GC reaction rather than as a master regulator in the mode of 
BCL6 or PRDM1.
MATERIALS AND METHODS
Mice, lymphomas, cell lines, and microarray analyses of gene ex-
pression. C57BL/6-Irf8−/− mice described previously (12) were studied at 
6–8 wk of age under a protocol (Lip-4) approved by the National Institute 
of Allergy and Infectious Diseases (NIAID) Animal Care and Use Commit-
tee. Splenic B cells were purifi  ed by negative selection using standard tech-
niques and were >95% pure. The NFS-202 cell line was cultured from the 
second generation scid passage of a spontaneous follicular B cell lymphoma 
from an NFS.V+ mouse. Plasmacytoma cell lines were provided by M. Pot-
ter (National Institutes of Health [NIH], Bethesda, MD). The origins and 
characteristics of primary B cell–lineage lymphomas from NFS.V+ congenic, 
B6.λ-MYC, SJL-β2m−/−, and BALB/c-gld/gld mice, and the techniques 
used for transcriptional profi  ling of the lymphomas using oligonucleotide 
  arrays, were detailed previously (39, 40). Microarray data is available under 
accession no. GSE1908.
Negative selection of human primary tonsillar B cells, transfection, 
sorting, and analyses of gene expression. For negative selection of B 
cells, tonsillar mononuclear cells were prepared (41, 42) and were stained on 
ice with a StemSep human B cell–negative selection cocktail containing a 
mixture of dextran cross-linked to mAb specifi  c for glycophorin A, CD2, 
CD3, CD14, CD16, and CD56, followed by exposure to a magnetic coil 
covalently linked to antidextran mAb (StemCell Technologies, Inc.). Poly-
styrene tubes (12 × 75 mm) containing the suspension were placed into 
purple EasySep magnets (Stem Cell Technologies). After 5 min at room 
temperature, the suspension of purifi  ed B cells was decanted into collection 
tubes. The cells were pelleted, resuspended in PBS 1% BSA, and counted.
For transfections, negatively selected tonsillar B cells were diluted to 
5 × 106 ml, separated into 1-ml aliquots, and pelleted. The supernatant was 
removed, and the cells were resuspended in 100 μl of nucleofector solution 
(Amaxa Biosystems). 5 μg of plasmid expressing EGFP or IRF8 tagged 
with EGFP (17), both gifts from K. Ozato (NIH, Bethesda, MD) was added 
to each tube and run on the U-15 program of the Amaxa nucleofector ma-
chine. 2 ml of room-temperature RPMI medium (Life Technologies) sup-
plemented with 200 U/ml penicillin G, 10 μg/ml gentamycin, and 10% 
FCS was added, and cells were placed in a 12-well plate to incubate at 
37°C overnight.
For sorting of EGFP+ and EGFP− populations, cells were harvested and 
resuspended in RPMI medium (Life Technologies) supplemented with 200 
U/ml penicillin G, 10 μg/ml gentamycin, and 10% FCS before using a cell 
sorter (MoFlo; DakoCytomation). For analysis, cells were stained with PE–
Cy7 anti–human CD38 (HD37 mIgG1; Becton Dickinson) and A647 anti–
human IgD (IA6-1 mIgG2a; BD Biosciences); the A647 conjugation kit was 
purchased from Invitrogen. PE–Cy7 and A647-conjugated isotype-matched 
mAbs were used as controls.
Aff  ymetrix arrays were used to profi  le gene expression in human tonsillar 
B cell subsets. RNA was prepared from tonsillar B cell subsets purifi  ed as 
  described previously (41). We studied RNA from three experiments for cen-
troblasts, plasma cells, and CD38− IgD+ cells and from four experiments for 
CD38−IgD− cells. The purifi  ed RNA was reverse transcribed into cDNA 
(Invitrogen). The template cDNA was purifi  ed for amplifi  cation and in vitro 
transcription reaction to cRNA (BioArray High Yield RNA transcript label-
ing kit [T7]; Enzo Life Sciences). cRNA was biotin labeled, purifi  ed, and hy-
bridized to HG-U133A Aff  ymetrix Genechips according to the Aff  ymetrix 
protocol (available at http://  w  w  w  .  a  ff  ymetrix.com). Genechips were scanned 
on a high-resolution Aff  ymetrix scanner using GCOS software (version 1.2). 
Microarray data were log2 transformed. Relative gene expression of tonsillar 
B cell subsets was determined by comparison with levels in IgD+ PBBs.70   REGULATION OF THE GC GENE PROGRAM BY IRF8/ICSBP | Lee et al.
siRNA knockdown of IRF8 expression. The mammalian expression 
vector pSUPER.retro.puromycin (OligoEngine) was used for expression of 
siRNA in NFS-202 cells. To generate the pSR.puro-IRF8 #2 and pSR.
puro-IRF8 #5, the pSUPER.retro.puromycin vector was digested with Bgl 
II and Hind III and the annealed oligos (IRF8 #2, 5′-gatccccA  C  C  A  C  C  A  C-
C  T  G  C  C  T  T  G  A  A  G  ttcaagagaC  T  T  C  A  A  G  G  C  A  G  G  T  G  G  T  G  G  T  tttt tggaaa-3′ 
and 5′-agcttttccaaaaaA  C  C  A  C  C  A  C  C  T  G  C  C  T  T  G  A  A  G  tctcttgaaC  T  T  C  A-
A  G  G  C  A  G  G  T  G  G  T  G  G  T  ggg-3′; IRF8 #5, 5′-gatccccA  C  T  C  A  T  T  C  T  G-
G  T  G  C  A  G  G  T  A  ttcaagagaT  A  C  C  T  G  C  A  C  C  A  G  A  A  T  G  A  G  T  tttttggaaa-3′ and 
5′-agcttttccaaaaaA  C  T  C  A  T  T  C  T  G  G  T  G  C  A  G  G  T  A  tctcttgaaT  A  C  C  T  G  C  A  C-
C  A  G  A  A  T  G  A  G  T  ggg-3′) were ligated into the vector. The 19-nucleotide 
IRF8 target sequences are indicated in capitals in the oligonucleotide se-
quences. A control vector (pSR.puro-negative) was constructed using 
64-nucleotide sequences (5′-gatccccT  G  T  A  G  A  T  G  G  G  T  A  C  G  C  G  C  T  C  ttcaa-
gagaG  A  G  C  G  C  G  T  A  C  C  C  A  T  C  T  A  C  A  tttttggaaa-3′ and 5′-agcttttccaaaaaT  G-
T  A  G  A  T  G  G  G  T  A  C  G  C  G  C  T  C  tctcttgaaG  A  G  C  G  C  G  T  A  C  C  C  A  T  C  T  A  C  A  ggg-3′) 
with no substantial homology to any mammalian gene sequence and thus 
serves as a nonsilencing control. The constructs were transformed into 
DH5α-competent cells (Invitrogen) according to the manufacturer’s in-
structions. Positives were confi  rmed by sequencing.
Retroviral infection and transfection of cell lines. Ecotropic retroviral 
supernatants were produced by transfection of phoenix packaging cells by a 
reagent (LipofectAMINE 2000; Invitrogen) according to the manufacturer’s 
instructions. After transfection (48 h), the tissue culture medium was fi  ltered 
through a 0.45-μm fi  lter, and the viral supernatant was used for infection of 
NFS-202 cells after addition of 4 μg/ml polybrene. Cells were infected for 
24 h and allowed to recover for 24 h with fresh medium. Infected cells were 
selected with 4 μg/ml puromycin for 72 h and cloned for 2 mo. Cloned cells 
were assayed for levels of IRF8 transcripts by qPCR.
Luciferase reporter assays. The 5′ fl  anking regions of Bcl6 (−1772/+245) 
and Aicda (−840/+79) were PCR amplifi  ed from genomic DNA extracted 
from NFS-202 cells and cloned into the pGL3–Basic Firefl  y luciferase re-
porter vector (Promega). +1 corresponds to the fi  rst nucleotide of exon 1 of 
the gene. A murine IRF8 expression vector (pCDNA3.1-IRF8) was pro-
vided by K. Ozato. The 800-ng reporter plasmid was used for transfection of 
HeLa cells grown in 12-well plates. The 50-ng pRL-SV40 Renilla luciferase 
vector (Promega) was used as an internal control. To test dosage eff  ects, 100, 
200, and 300 ng of pCDNA3.1-IRF8 expression vector were adjusted to a 
total 300 ng of plasmid with pCDNA3.1 empty vector. Luciferase activities 
were measured 22 h after transfection using the dual-luciferase reporter 
assay kit (Promega) according to the manufacturer’s protocol. All samples 
were tested in triplicate.
Western blotting. Total cell lysates were prepared in lysis buff  er (20 mM 
Hepes, pH 7.5, 150 mM NaCl, 0.2 mM EDTA, 0.1% Nonidet P-40, 1 mM 
DTT, 10% glycerol) supplemented with protease inhibitor cocktail solution 
(Pierce Chemical Co.). Lysates were cleared by centrifugation at 14,000 g 
for 20 min at 4°C, and the protein contents were then determined by the 
BCA protein assay kit (Pierce Chemical Co.). For Western blotting, 20 µg 
of protein per lane was separated on a NuPage 10% Bis-Tris gel (Invitrogen) 
and transferred to a polyvinylidene difl  uoride membrane. After blocking 
with a 5% skim milk solution, the blot was incubated with anti-IRF8 
  antibody (Santa Cruz Biotechnology, Inc.) or anti–α-tubulin antibody 
(Sigma-Aldrich). These antibodies were detected with horseradish peroxi-
dase–conjugated donkey anti–rabbit or anti–mouse secondary antibody (GE 
Healthcare) and developed by Super Signal detection kit (Pierce Chemical 
Co.) according to the manufacturer’s instructions.
qPCR. Total RNA was isolated using a modifi  ed version of the RNA ex-
traction protocol detailed elsewhere (available at http://research.nhgri.nih.
gov/microarray). In brief, total RNA was collected using the initial steps of 
the TRIzol protocol (Invitrogen). After collecting the aqueous supernatant, 
the RNeasy column coupled with DNase set–based (QIAGEN) protocol 
was followed. Reverse transcription was performed using 2 µg total RNA, 
25 µg/ml oligo (dT)12-18 primers, and 200 units of SuperScript II reverse 
transcriptase (Invitrogen). For qPCR, 2 ng cDNA was amplifi  ed  using 
SYBR Green PCR Master Mix (Applied Biosystems) and 0.33 µM each of 
forward and reverse primers on the ABI PRISM 7900HT sequence detector 
system (Applied Biosystems) with published techniques (43). Primers for 
qPCR were designed using the Primer Express software (Applied Bio-
systems) and synthesized at MWG-Biotec (Tables S1 and S2, available at 
http://  w  w  w  .  j  em.org  /  cgi  /  content  /  full  /  jem.20051450/DC1). All samples were 
tested in triplicate, and mean values were used for quantifi  cation. Analysis 
was performed using software (SDS version 2.1; Applied Biosystems) ac-
cording to the manufacturer’s instructions. Samples were normalized using 
the housekeeping gene GAPDH for human studies and β-actin for mouse. 
Results for human cells are expressed as the relative fold increase compared 
with normal IgD+ PBBs. Assays of peripheral blood and tonsillar B cells 
were run in separate plates, compared with β-actin as a control, and normal-
ized to IgD+ PBBs.
ChIP assays. ChIP assays were performed by using the ChIP assay kit 
  (Upstate Biotechnology) according to the manufacturer’s protocol. 4 × 106 
cells were cross-linked with 1% formaldehyde for 10 min at room temperature 
before ChIP assays. The chromatin was immunoprecipitated with goat anti-
IRF8 Ab or preimmune goat IgG (Santa Cruz Biotechnology, Inc.) was used 
as a control Ab. A 3-µl aliquot out of the 60-µl solution of DNA recovered 
from each immunoprecipitate was used for PCR, and the products were ana-
lyzed on a 2% agarose gel after 36 cycles of amplifi  cation. Input DNA (1:400) 
was used as a control. The following primers were used for PCR: mouse Bcl6 
promoter (5′-G  T  G  C  C  T  A  A  T  A  C  T  C  T  A  G  C  T  G  G  A  A  G  G  A  G  -3′ and 5′-G  C  T-
C  G  G  C  C  T  C  T  G  G  A  A  T  T  C  T  -3′), mouse Bcl6 10-kb 5′ region (5′-C  C  A  A  A  G-
T  T  C  T  G  G  A  A  T  G  C  C  C  A  -3′ and 5′-C  A  G  C  A  T  A  T  C  C  G  T  G  C  A  T  G  T  G  C  -3′), 
human  BCL6 promoter (5′-A  A  G  T  G  C  A  G  G  A  G  A  G  A  C  A  C  A  C  T  T  C  A  G  -3′ 
and 5′-C  A  T  A  T  G  T  A  A  C  A  A  T  C  C  C  A  G  C  C  C  C  -3′), human BCL6 10-kb 5′ 
region (5′-T  A  T  T  G  T  A  A  T  T  T  A  C  T  T  A  A  T  C  A  T  T  C  T  T  C  A  T  C  C  A  A  -3′ and 
5′-G  C  A  G  A  C  C  C  T  T  T  G  A  C  C  C  A  G  A  G  -3′), mouse Aicda promoter (5′-A  C  A-
T  G  G  T  G  G  C  T  T  T  C  A  A  C  C  G  -3′ and 5′-G  C  A  T  C  C  A  G  A  G  A  G  T  G  A  A  C  T  T  T-
A  G  C  C  -3′), mouse Aicda 10-kb 5′ region (5′-T  T  C  C  T  A  T  G  G  C  A  T  G  T  G  T  A-
C  G  G  C  -3′ and 5′-A  A  C  A  C  T  C  T  T  C  G  G  G  C  C  A  A  T  G  A  -3′), human AICDA 
promoter (5′-T  A  G  C  A  T  T  G  C  A  T  C  C  C  T  A  G  C  A  C  C  -3′ and 5′-T  G  G  T  C  T-
A  T  T  A  A  A  G  A  T  T  T  T  A  T  T  T  C  T  C  T  C  T  C  C  T  -3′), human AICDA 10-kb 5′ 
region (5′-G  T  C  T  C  T  A  C  T  G  A  A  A  A  T  A  C  A  A  A  A  A  A  A  T  T  G  G  C  T  -3′ and 5′-
  A  C  T  G  C  A  A  C  C  T  C  T  G  C  C  T  C  C  C  -3′), mouse Gapdh promoter (5′-C  A  C  C  C-
T  G  G  C  A  T  T  T  T  C  T  T  C  C  A  -3′ and 5′-G  A  C  C  C  A  G  A  G  A  C  C  T  G  A  A  T  G  C  T  G  -
3′), and human GAPDH promoter (5′-G  C  C  T  G  A  G  C  A  G  T  C  C  G  G  T  G  T  -3′ 
and 5′-G  A  T  C  G  G  T  G  C  T  G  G  T  T  C  C  C  A  -3′).
Online supplemental material. Fig. S1 shows the relative expression of IRF8 
in mouse lymphomas and plasmacytomas. Fig. S2 depicts fl  ow cytometric ana-
lyses of CD19+ tonsillar B cells transfected with vectors expressing EGFP only 
or WT IRF8 tagged with EGFP at 18 h after infection. Tables S1 and S2 show 
mouse and human primers, respectively, for qPCR. Online supplemental mate-
rial is available at http://www.jem.org/cgi/content/full/jem.20051450/DC1.
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